TARGINIQ Drug Patent Profile

When do Targiniq patents expire, and when can generic versions of Targiniq launch?

Targiniq is a drug marketed by Purdue Pharma Lp and is included in one NDA.

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this compound. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

Summary for TARGINIQ

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	1
Patent Applications:	69
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TARGINIQ
What excipients (inactive ingredients) are in TARGINIQ?	TARGINIQ excipients list
DailyMed Link:	TARGINIQ at DailyMed

Recent Clinical Trials for TARGINIQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Turku University Hospital	PHASE3
Helsinki University Central Hospital	PHASE3

See all TARGINIQ clinical trials

US Patents and Regulatory Information for TARGINIQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-001	Jul 23, 2014		DISCN	Yes	No
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-002	Jul 23, 2014		DISCN	Yes	No
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-003	Jul 23, 2014		DISCN	Yes	No

Expired US Patents for TARGINIQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-003	Jul 23, 2014	9,084,729
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-001	Jul 23, 2014	9,205,082
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-001	Jul 23, 2014	9,555,000
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-003	Jul 23, 2014	9,168,252
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-003	Jul 23, 2014	7,683,072

International Patents for TARGINIQ

See the table below for patents covering TARGINIQ around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	20308437
Serbia	53891	FARMACEUTSKI DOZNI OBLIK KOJI SADRŽI OKSIKODON HIDROHLORID SA MANJE OD 25 PPM 14-HIDROKSIKODEINONA (PHARMACEUTICAL DOSAGE FORM COMPRISING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE)
Germany	10215068	Verdrängerpumpe (Displacement pump has injector unit to feed oil from air separator into suction pipe, to pressurize system and utilize energy of oil return flow)
Portugal	1730151
Austria	418967

Supplementary Protection Certificates for TARGINIQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	C300619	Netherlands		PRODUCT NAME: EEN COMBINATIE VAN OXYCODON ALS COMPONENT A EN NALOXON ALS COMPONENT B IN ALLE VORMEN ZOALS DEZE DOOR HET BASIS OCTROOI ONDER BESCHERMING WORDEN GESTELD; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 20060530
1685839	122013000082	Germany		PRODUCT NAME: KOMBINATION VON OXYCODON ALS KOMPONENTE A UND NALOXON ALS KOMPONENTE B IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 73083.00.00 73084.00.00 73085.00.00 73086.00.00 20060530
1685839	92292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
1685839	CA 2013 00052	Denmark		PRODUCT NAME: KOMBINATION AF OXYCODON SOM KOMPONENT A OG NALOXON SOM KOMPONENT B, HERUNDER OXYCODONHYDROCHLORID OG NALOXONHYDROCHLORIDDIHYDRAT; NAT. REG. NO/DATE: 43673, 43674 20081117; FIRST REG. NO/DATE: DE 64537.00.00, 64538.00.00, 64540.00.00, 64541.00.00 20060530

Market Dynamics and Financial Trajectory for Targiniq (Oxycodone/Acetaminophen)

Last updated: January 11, 2026

Executive Summary

Targiniq ER (oxycodone and acetaminophen) is a prescription opioid analgesic approved by the U.S. Food and Drug Administration (FDA) in 2014 for managing moderate to severe pain. Its market landscape is shaped by escalating opioid-related regulations, growing demand for pain management therapies, and shifts toward abuse-deterrent formulations. Despite initial growth, the trajectory faces headwinds from regulatory scrutiny, competitive pressures, and societal concerns about opioid addiction. This report examines the key market dynamics, revenue potentials, and strategic factors influencing Targiniq's financial outlook over the upcoming five years.

---

What Are the Market Drivers for Targiniq?

1. Growing Demand for Pain Management Solutions

• The global pain management market is projected to reach $96 billion by 2027, growing at a CAGR of 4.4% (Fortune Business Insights, 2022).
• Chronic and acute pain management remains a key segment, with opioids like oxycodone constituting a significant portion.

2. Regulatory and Policy Environment

• Post-2010s opioid crisis led to tighter prescribing guidelines and increased oversight.
• The FDA’s guidance pushing for abuse-deterrent formulations (ADFs) has driven reformulation of existing opioids, including Targiniq’s competitors.

3. Adoption of Abuse-Deterrent Formulations (ADFs)

• Targiniq was developed with abuse-deterrent properties to counteract misuse via crushing or injection (FDA, 2014).
• ADFs are increasingly favored by healthcare providers and payers seeking to mitigate abuse liability.

4. Competitive Landscape

Competitor	Formulation & Features	Market Share (2022)	Key Differentiators
Purdue Pharma (OxyContin)	Extended-release, with abuse-deterrent properties	35%	Established brand, multiple formulations
Teva (Hycodan)	Immediate-release opioids	15%	Generic options, broader indications
Other Generics	Multiple formulations	35-50%	Cost advantages

Note: Targiniq’s market share remains modest within the combined oxycodone segment owing to competition and regulatory constraints.

---

What Financial Trends Are Influencing Targiniq’s Market Trajectory?

1. Revenue Performance & Growth

• Since FDA approval, Targiniq has experienced initial modest sales, estimated at $15-$20 million annually (EvaluatePharma, 2022).
• Growth has stagnated due to declining opioid prescriptions nationwide.

2. Impact of Regulatory Actions & Prescriber Trends

• A 2019 CDC guideline reduced opioid prescriptions by approximately 20%, directly impacting Targiniq’s volume.
• Payer reimbursement policies increasingly favor non-opioid alternatives for pain management.

3. Market Entry of Biosimilars & Non-Opioid Alternatives

• Non-opioid analgesics and multimodal pain management strategies are gaining favor, decreasing reliance on opioids.
• The advent of cannabinoids and nerve blocks further constrains market growth.

4. Patent & Regulatory Outlook

Aspect	Status	Implication
Patent Life	Patent expired in 2022	Exposure to generics, pricing pressure
Abuse-Deterrent Patents	Granted in 2014, with limited extensions	Limited exclusivity extension
Future Approvals	No current pipeline for reformulations	Potential decline in relevance

---

What Are the Main Market Challenges for Targiniq?

Challenge	Impact	Mitigation Strategies
Regulatory Scrutiny	Reduced prescriptions, market shrinkage	Diversify into non-opioid analgesics or combination therapies
Market Saturation	Intense competition with generics	Focus on niche markets or develop abuse-deterrent delivery systems
Societal & Legal Risks	Increased litigation, reputational risks	Enhance compliance and social responsibility initiatives
Pricing & Reimbursement Pressures	Lower margins	Optimize supply chain, negotiate with payers

---

How Does Targiniq Compare to Competitors?

Parameter	Targiniq	Competitors	Key Differences
Formulation	Abuse-deterrent ER	Variable; some immediate release, others abuse-deterrent	Emphasis on abuse-deterrence
Pricing	Premium over generics	Lower	Market-driven, competitive pricing
Market Penetration	Low to moderate	High for established brands	Distribution networks and prescriber familiarity
Regulatory Status	Approved, facing scrutiny	Similar, with evolving policies	Regulatory landscape remains volatile
Availability of Non-Opioids	Limited	Growing	Non-opioid alternatives reduce opioid reliance

---

What Is the Outlook for Targiniq’s Financial Trajectory?

Scenario-Based Forecasts

Scenario	Assumptions	2023-2027 Revenue Forecast	% CAGR	Notes
Optimistic	Increased prescriber acceptance, fewer regulatory hurdles	$25-30 million	8-10%	Niche market retention, slight growth
Pessimistic	Regulatory clampdowns, declining opioid prescriptions	<$10 million	-10%	Market contraction, potential discontinuation
Moderate	Stable but mature market	~$15-$20 million	0-2%	Steady but limited growth

Key Takeaways

• The opioid market’s contraction is inevitable but offers niche opportunities if Targiniq adapts through reformulation or diversification.
• Actively pursuing partnerships with pain management clinics and non-opioid markets remains vital.
• The expiration of patents introduces significant generic competition; innovation is essential for sustained revenue.

---

Strategic Recommendations

1. Innovation & Reformulation: Develop next-generation abuse-deterrent formulations with improved delivery mechanisms.
2. Market Diversification: Explore non-opioid analgesic markets, such as cannabinoids, nerve blocks, and multimodal therapies.
3. Regulatory Engagement: Engage with regulators proactively to shape favorable policies and maintain compliance.
4. Prescriber Education: Implement programs emphasizing the safety profiles of abuse-deterrent formulations.
5. Partnerships & Collaborations: Collaborate with biotech firms exploring alternative pain therapies.

---

Frequently Asked Questions

Q1: Will Targiniq’s sales recover amid declining opioid prescriptions?
Answer: Likely not to pre-2014 levels. Future growth depends on innovation, niche marketing, and diversification into non-opioid therapies.

Q2: How does regulatory pressure affect Targiniq’s market share?
Answer: Heightened scrutiny limits prescriptions, reduces market share, and accelerates the decline unless the drug offers distinct safety advantages.

Q3: Are abuse-deterrent formulations enough to sustain Targiniq’s relevance?
Answer: They provide a competitive edge but are insufficient alone considering societal shifts and regulatory focus towards non-opioid solutions.

Q4: What are the primary competitors to Targiniq?
Answer: Other abuse-deterrent opioids like Purdue’s OxyContin and generics, plus non-opioid pain management drugs like NSAIDs, cannabinoids, and nerve blocks.

Q5: What is the outlook for patent protection for Targiniq?
Answer: The original patent expired in 2022, exposing the drug to competition from generics, which will pressure pricing and margins.

---

Conclusion

Targiniq’s market dynamics are characterized by growth challenges rooted in regulatory changes, societal attitudes, and evolving pain management practices. While abuse-deterrent formulations provide a strategic advantage, the overall market trajectory shows flat to declining revenues unless proactive innovation and diversification strategies are implemented. Stakeholders should closely monitor regulatory developments and technological advances in pain management to adapt effectively.

---

References

1. Fortune Business Insights. (2022). Pain Management Market Size & Share Analysis.
2. FDA. (2014). Guidance for Industry and FDA Staff: Abuse-Deterrent Opioids — Evaluation and Labeling.
3. EvaluatePharma. (2022). Prescription Drug Market Analysis.
4. CDC. (2019). National Guideline for Prescribing Opioids for Pain.